Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Recognize the differences between immunotherapeutic agents and chemotherapeutic agents: mechanisms of action, adverse effects, and toxicity management
Recognize pivotal clinical trials for the treatment of urothelial carcinomas of the bladder
Identify the signs and symptoms of serious or life-threatening adverse effects of immunotherapeutic agents
Develop education pearls to educate patients on the recognition of immune-related toxicities
Summarize the role of immunotherapeutic agents to patients with UCB according to established guidelines
*
1 (Low)2345 (High)
Emily Lemke, DNP, AGPCNP-BC, AOCNP
Amishi Shah, MD
*
*